Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allegra Sales Decline Will Not Prompt OTC Switch, Aventis Says

This article was originally published in The Tan Sheet

Executive Summary

Decreasing Allegra sales in the face of increased competition from OTC antihistamines will not lead Aventis to pursue a switch for the drug, the firm stated during an Oct. 30 call on third-quarter results

You may also be interested in...



Allegra Faces Increasing Challenges In Rx Drug Arena

Obstacles to marketing second generation, non-sedating antihistamine Allegra effectively as a prescription drug have escalated substantially in the past year, according to Aventis

Allegra Faces Increasing Challenges In Rx Drug Arena

Obstacles to marketing second generation, non-sedating antihistamine Allegra effectively as a prescription drug have escalated substantially in the past year, according to Aventis

Allegra Faces Increasing Challenges In Rx Drug Arena

Obstacles to marketing second generation, non-sedating antihistamine Allegra effectively as a prescription drug have escalated substantially in the past year, according to Aventis

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel